Return-to-libc Attacks in Medical Device Cybersecurity

What is a return-to-libc attack (ret2libc)?

A return-to-libc attack is typically associated with a vulnerability that allows an attacker to overwrite control flow (such as a return address). The attacker attempts to redirect execution to an existing library routine already mapped in process memory-often to perform a privileged action without injecting custom shellcode.

High-level background: Return-to-libc attack overview.

Why this matters for connected medical devices

Medical device cybersecurity isn’t just “device firmware.” Many real-world attack paths involve the broader product system:

• Device firmware and embedded OS components
• Companion apps and desktop utilities used by clinicians or field service
• Gateways, connectivity modules, and protocol translators
• Cloud services that process device data (especially parsers and protocol handlers)
• Software update and build/signing infrastructure

Memory corruption vulnerabilities show up most often where software handles untrusted inputs: network traffic, file imports/exports, device telemetry, or protocol parsing. If exploited, they can contribute to availability impacts, integrity issues, or unauthorized actions-risk areas that can intersect with patient safety.

How modern mitigations reduce ret2libc risk

Ret2libc is harder today than it was 15-20 years ago because modern platforms combine multiple layers of memory protection. Defenders should treat these as a baseline, then validate they’re truly enabled in production builds.

Memory protection mechanisms to verify

• Data Execution Prevention (DEP/NX): reduces execution from non-executable memory regions.
• Address Space Layout Randomization (ASLR): randomizes memory locations, making reliable redirection more difficult.
• Stack-smashing protection (stack canaries): helps detect stack corruption before control flow is hijacked.
• Modern compiler/linker hardening: position-independent executables (PIE), RELRO, fortified functions, and similar controls (platform-dependent).

NIST explicitly calls out DEP and ASLR as examples of memory protection controls. NIST SP 800-53 (SI-16) Memory Protection reference.

The bigger trend: reducing memory corruption at the source

Hardening helps, but it doesn’t eliminate the underlying class of bugs. In June 2025, CISA and NSA published guidance emphasizing the value of memory safe languages as a approach to reducing memory-related vulnerabilities.

CISA/NSA: Memory Safe Languages guidance

For medical device organizations, “memory safe languages” doesn’t mean rewriting everything immediately. Practical approaches include:

• New modules in memory safe languages where feasible
• Safer libraries for parsing and serialization
• Clear boundaries: isolate high-risk parsers and restrict privileges
• Secure coding standards and aggressive input validation

How this supports FDA-aligned lifecycle cybersecurity (SPDF + TPLC)

FDA’s current cybersecurity guidance emphasizes building cybersecurity into the quality system and maintaining it across the Total Product Lifecycle (TPLC). A practical way to align is to treat memory corruption risk reduction as part of your Secure Product Development Framework (SPDF): prevent bugs where possible, harden what remains, and validate controls continuously.

FDA: Cybersecurity in Medical Devices (Premarket Guidance)

What “good” looks like in a medical device secure development program

1) Engineering controls

• Secure coding requirements for memory-unsafe languages (C/C++)
• Threat modeling that includes memory corruption abuse cases and entry points
• Build configurations that enforce platform hardening in release builds
• Component inventory (SBOM) to manage third-party library exposure

2) Verification and validation

See also: When to Hire a Device Security Consultant vs. Build In-House, Cybersecurity Is Now a QMS Requirement, and Why Medical Device Cybersecurity Is Nothing Like Enterprise.

• Static analysis tuned for memory safety patterns
• Fuzz testing for parsers, protocol handlers, and file import/export
• Penetration testing that includes memory corruption risk areas (as scoped and authorized)
• Evidence: documented test plans, results, and remediation verification

Related Blue Goat resources:

• Medical Device Threat Modeling Services
• Medical Device Penetration Testing Services
• FDA-Compliant SBOM Services for MedTech
• FDA Premarket Cybersecurity Services

Common mistakes that keep ret2libc risk alive

• Assuming hardening is “on by default” without verifying build flags and runtime settings.
• Ignoring legacy parsers and “rarely used” file handling paths.
• Testing only at the end instead of using analysis + fuzzing during development.
• Not tracking third-party libraries (no SBOM, unclear versions, slow patch response).

Key Takeaways

• Return-to-libc is a memory exploitation technique that can use existing code in memory after a memory corruption bug.
• Modern mitigations (DEP/NX, ASLR, stack protections) reduce exploitability-verify they’re enabled in production builds.
• Reducing memory vulnerabilities at the source is increasingly emphasized, including adoption of memory safe languages where feasible.
• For medical device cybersecurity, the winning approach is lifecycle: secure design, hardening, and repeatable validation evidence.

Table of Contents

• What is a return-to-libc attack (ret2libc)?
• Why this matters for connected medical devices
• How modern mitigations reduce ret2libc risk
• The bigger trend: reducing memory corruption at the source
• How this supports FDA-aligned lifecycle cybersecurity (SPDF + TPLC)
• What “good” looks like in a medical device secure development program
• Common mistakes that keep ret2libc risk alive
• Key Takeaways
• Next step

How Blue Goat approaches this

Blue Goat Cyber helps medical device manufacturers identify and mitigate return-to-libc vulnerabilities across the entire product ecosystem. Our approach focuses on scrutinizing device firmware, companion applications, cloud infrastructure, and supporting systems for potential memory corruption flaws. We perform in-depth binary analysis and penetration testing to uncover specific weaknesses that could enable ret2libc or similar exploits.

Our team of cybersecurity experts, many holding CISSP and OSCP certifications and with ex-military red team experience, conducts detailed assessments to validate the effectiveness of memory protection mechanisms like ASLR, DEP, and stack canaries. We also advise on secure development practices, including the adoption of memory-safe languages and frameworks, to prevent these vulnerabilities at their source. We aim to ensure your devices meet and exceed regulatory cybersecurity expectations, including the FDA's guidance. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our validation services: Medical Device Penetration Testing.

FAQ

Is return-to-libc still relevant today?

Yes. While modern mitigations make exploitation harder, memory corruption bugs still exist-especially in legacy code, complex parsers, and third-party components. Defense should focus on prevention, hardening, and validation.

How do ASLR and DEP reduce ret2libc risk?

DEP/NX reduces execution from non-executable regions, while ASLR makes memory locations unpredictable. Together (plus other controls), they reduce reliability of control-flow hijacking and redirection attacks.

Do medical devices commonly have memory corruption risks?

They can-particularly when firmware or supporting software uses C/C++, includes third-party libraries, or processes untrusted inputs such as network traffic or imported files. The risk varies by architecture and exposure.

What’s the best way to reduce memory corruption vulnerabilities?

A layered approach works best: secure coding practices, rigorous input validation, compiler/linker hardening, fuzzing for risky parsers, and a longer-term roadmap for memory safe languages where feasible.

How does this connect to FDA expectations?

FDA’s guidance emphasizes lifecycle cybersecurity, including secure development processes and evidence that controls are implemented and validated. Addressing memory corruption risk is a practical part of that story.

Next step

If you want to reduce memory corruption risk and produce FDA-aligned evidence (threat modeling, SBOM, testing plans, and verification results), we can help.

Book a Discovery Session

About the author

Christian Espinosa, CISSP, Founder, Blue Goat Cyber. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. Read more about Christian.